Section I — Coach Water — Clinical Nephrology and Water Translation
This section covers the Master's chapter on Clinical Nephrology and Water Translation, Lessons 1 through 5: Clinical Nephrology — CKD, AKI, and the Modern Treatment Landscape; Fluid and Electrolyte Clinical Practice; Hydration Clinical Research at Translational Depth; Water Security and Environmental Health at Structural Public Health Depth; and the Integrated Water Translational Frame and Bridge to Integrative Synthesis. All material is already in the chapter — no new content.
Part A — Vocabulary (20 points, 2 points each)
Select the single best answer for each question.
1. Heerspink et al. 2020 NEJM DAPA-CKD trial (foundational anchor):
A) Was a hypertension trial B) Randomized 4,304 CKD patients (eGFR 25-75, UACR 200-5000, with and without type 2 diabetes) to dapagliflozin 10 mg daily versus placebo on top of ACEi/ARB; primary composite outcome HR 0.61 (95% CI 0.51-0.72, p<0.001); trial stopped early for efficacy; established SGLT2 inhibitor paradigm shift across diabetic and non-diabetic CKD C) Was a sleep trial D) Has been superseded
2. EMPA-KIDNEY trial (Herrington 2023 NEJM):
A) Tested empagliflozin in heart failure B) Confirmed and extended SGLT2 renoprotection in broader CKD population (6,609 patients, eGFR 20-45 or eGFR 45-90 with UACR ≥200); HR 0.72 for kidney disease progression or cardiovascular death; included 54% non-diabetic; informed 2024 KDIGO CKD guideline positioning SGLT2 inhibitors alongside RAAS blockade as standard renoprotective therapy C) Was a sodium study D) Has been superseded
3. KDIGO 2024 CKD staging:
A) Uses eGFR alone B) Two-axis framework — GFR categories G1-G5 (≥90 to <15) and albuminuria categories A1-A3 (<30 to >300 mg/g) — producing combined risk stratification grid (G1A1 lowest risk, G5A3 highest); the two-axis approach replaced older single-axis (GFR-only) framework because albuminuria adds independent prognostic information C) Uses albuminuria alone D) Has been superseded
4. CKD-EPI 2021 race-free equation (Inker 2021 NEJM):
A) Retained the race coefficient B) Race-free creatinine-based eGFR equation following the 2020-2021 NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease — concluded race is social rather than biological construct, that race coefficient could delay nephrology referral and transplantation eligibility for Black patients, and that race-free equation is more equitable and methodologically defensible C) Has been superseded D) Applies only to research
5. Sterns 2015 NEJM ODS framework:
A) Was a sodium-loading study B) Clinical decision framework for chronic hyponatremia correction limits — ≤8-10 mEq/L per 24h (standard risk), ≤6 mEq/L per 24h (high-risk: chronic alcoholism, malnutrition, hypokalemia, advanced liver disease), ≤18 mEq/L per 48h; DDAVP clamp rescue framework for over-correction; foundational for avoiding osmotic demyelination syndrome C) Has been superseded D) Applies only to pediatric
6. K-binders: patiromer and sodium zirconium cyclosilicate:
A) Are antibiotic agents B) Non-absorbed oral potassium binders — patiromer (calcium-based polymer, OPAL-HK Weir 2015 NEJM, PEARL-HF Pitt 2015 EHJ) and sodium zirconium cyclosilicate (HARMONIZE Packham 2015 NEJM) — enable continuation of RAAS-blockade-plus-SGLT2 in CKD patients who would have required RAAS-blockade dose reduction or discontinuation for chronic hyperkalemia C) Have been superseded D) Apply only to acute hyperkalemia
7. STARRT-AKI trial (Bagshaw 2020 NEJM):
A) Demonstrated benefit of accelerated KRT B) Randomized 3,019 critically ill adults with severe AKI to accelerated KRT initiation (within 12h) versus standard (KRT at clinical indication); no significant difference in 90-day mortality; accelerated strategy had higher 90-day KRT dependence (10.4% vs 6.0%); informs 2024 KDIGO AKI guideline approach using clinical indications rather than absolute creatinine/GFR threshold for KRT initiation C) Has been superseded D) Was unrelated to KRT
8. Hew-Butler 2015 Third International EAH Consensus:
A) Recommends maximum water intake B) The operating clinical decision framework for exercise-associated hyponatremia — dilutional hyponatremia from excessive fluid intake with SIADH-like ADH pattern; recognition framework with point-of-care sodium at race medical tents; acute management with hypertonic saline (3% NaCl 100 mL boluses) for severe symptomatic EAH targeting initial 4-6 mEq/L rise; cross-references Water Master's L3, Move Master's L4, Hot Master's L1 C) Has been superseded D) Recommends water restriction
9. EPA 2024 PFAS final MCL rule:
A) Voluntary guidance B) The April 2024 EPA final National Primary Drinking Water Regulation for PFAS — first enforceable federal MCLs for six PFAS in drinking water (PFOA 4 ppt, PFOS 4 ppt, PFHxS 10 ppt, PFNA 10 ppt, HFPO-DA 10 ppt, plus mixtures via PFAS Hazard Index); compliance by 2029; major regulatory action representing most significant emerging contaminant regulation in decades C) Has been superseded D) Has no enforcement
10. Marfella 2024 NEJM microplastics in atheroma:
A) Was an animal study B) Analyzed carotid atherosclerotic plaque from 257 endarterectomy patients — detected microplastics/nanoplastics in 58% of plaques with associated higher risk of cardiovascular events at 34-month follow-up; first major human cardiovascular outcome association for microplastics; opens demonstrated-pathology phase beyond detection-in-tissues literature (Leslie 2022 Environment International blood detection, placenta/lung/breast milk detection) C) Has been superseded D) Demonstrated no association
Part B — Concept Comprehension (20 points, 2 points each)
Select the single best answer for each question.
11. RAAS-blockade-plus-SGLT2 inhibitor era in CKD:
A) Has been superseded B) The post-2020 paradigm in proteinuric CKD — RAAS blockade (ACE-i or ARB) plus SGLT2 inhibitor as standard renoprotective therapy, with K-binders enabling continuation at maximally tolerated doses; the two classes operate through distinct mechanisms (RAAS reducing efferent arteriolar tone and proteinuria; SGLT2 inhibition reducing afferent hyperfiltration via tubuloglomerular feedback) and produce additive renoprotective effects C) Has been resolved D) Applies only to diabetic CKD
12. SIADH versus cerebral salt wasting differential:
A) Has same management B) Both produce hyponatremia in CNS injury; SIADH (euvolemic, normal/low urine output, high urine Na, often low uric acid) — treated with fluid restriction; CSW (hypovolemic with high urine output, high urine Na, often elevated BUN/Cr from volume depletion) — treated with volume expansion (saline); misclassifying CSW as SIADH and restricting fluids worsens volume status; the distinction matters clinically C) Has been resolved D) Applies only to elderly
13. Critical care fluid management at Master's depth:
A) "More fluid is better" B) Modern era shifted post-Rivers 2001 EGDT through ProCESS/ARISE/ProMISe 2014-2015 to CLASSIC (Meyhoff 2022 NEJM) and PETAL CLOVERS (Shapiro 2023 NEJM) supporting safety of restrictive approaches in septic shock; 2024 Surviving Sepsis Campaign reflects post-CLASSIC era with individualized fluid management guided by hemodynamic assessment and dynamic responsiveness measures C) Has been resolved D) Applies only to elderly
14. Bernard 1865 milieu intérieur at Master's clinical translational closure:
A) Has no clinical role B) Returns at Master's Lesson 5 operationalized through 21st-century clinical infrastructure — BMP/CMP as routine internal environment assessment, dialysis (Kolff 1944), critical care fluid management, KDIGO frameworks, EPA water policy; completes the multi-tier Coach Water arc (K-12 → Associates → Bachelor's → Master's) and bridges to Master's integrative final C) Has been superseded D) Applies only to research
15. Volkert 2019 ESPEN geriatric hydration guideline:
A) Has no clinical framework B) European Society for Clinical Nutrition and Metabolism clinical practice guideline on nutrition and hydration in geriatrics — addresses blunted thirst response, reduced renal concentrating capacity, caregiver dependence, dementia limitation, medication effects; recommends ~1500-2000 mL/day for most older adults without contraindications with individual adjustment; foundational geriatric hydration framework C) Has been resolved D) Applies only to pediatric
16. Hanna-Attisha 2016 AJPH Flint study:
A) Was a national survey B) Foundational primary literature on Flint water crisis — spatial analysis of pediatric blood lead level data before/after the 2014-2015 Flint River water source switch demonstrating doubling of children with blood lead ≥5 µg/dL; established environmental injustice landmark case driving EPA 2024 LCRR and broader U.S. water infrastructure investment cycle C) Has been superseded D) Was a national-cohort study
17. Stewart vs Henderson-Hasselbalch acid-base frameworks:
A) Same framework B) Henderson-Hasselbalch treats bicarbonate as central regulated variable (standard clinical framework using anion gap and delta-delta interpretation); Stewart approach treats pH as dependent variable determined by SID, Atot, and PaCO2 as three independent variables (added value in critical care with multiple concurrent disorders and altered albumin); frameworks complementary rather than competing C) Has been superseded D) Apply only to research
18. Wellness-industry "functional water" claims at five-point framework depth:
A) All claims have equal support B) Alkaline water — physiologically incoherent (stomach pH 1-2 neutralizes any ingested water); structured water — physically incoherent (hydrogen bonding picosecond dynamics); hydrogen water — most mechanistic coherence (H2 reactivity with hydroxyl radical and peroxynitrite) but intervention evidence ahead of claims; all three fail the marketing-grade claim per five-point framework C) Has been validated D) Has been resolved
19. EPA 2024 LCRR (Lead and Copper Rule Revisions):
A) Voluntary guidance B) Mandatory full lead service line replacement within 10 years (limited exceptions), action level lowered from 15 to 10 µg/L, strengthened tap sampling, public notification, schools/child-care testing; 2021 Bipartisan Infrastructure Law $15B allocation for lead service line replacement; EPA estimates 9-10 million lead service lines remain in U.S. C) Has been superseded D) Applies only to residential
20. Coach Water integrator position at Master's depth (Internal Environment):
A) Is abstract B) The Internal Environment position at Master's translational depth holds clinical nephrology (Water L1) including SGLT2 paradigm shift, fluid and electrolyte clinical practice (Water L2) with Sterns 2015 ODS framework, hydration clinical research (Water L3) with EAH consensus and wellness-industry-research-gap closure, water security and environmental health (Water L4) with EPA 2024 regulatory frameworks, and integrated water translational frame (Water L5) with Bernard 1865 returning at clinical translational closure completing the multi-tier arc and bridging to Master's integrative final C) Same as Substrate D) Same as Synchronizer
Part C — Application (30 points, 6 points each)
Write 5-7 complete sentences with specific reference to chapter content, primary literature citations, and methodological framings where asked.
21. Heerspink 2020 DAPA-CKD and the SGLT2 paradigm shift in nephrology. Walk the Heerspink et al. 2020 NEJM DAPA-CKD trial design (4,304 CKD patients, eGFR 25-75 with UACR 200-5000, with and without type 2 diabetes, dapagliflozin 10 mg daily versus placebo on top of ACE-i/ARB), findings (primary composite HR 0.61, trial stopped early for efficacy, effect consistent in non-diabetic subgroup), and downstream impact (Herrington 2023 EMPA-KIDNEY confirmation, 2024 KDIGO CKD guideline incorporating SGLT2 inhibitors alongside RAAS blockade). Position DAPA-CKD as the Master's chapter foundational anchor alongside other Master's clinical-translational anchors.
22. Sterns 2015 ODS framework and SIADH versus CSW clinical differential. Walk the Sterns 2015 NEJM clinical decision framework for chronic hyponatremia correction limits — ≤8-10 mEq/L per 24 hours standard risk, ≤6 mEq/L in high-risk patients, ≤18 mEq/L per 48 hours, with DDAVP clamp rescue framework. Apply the framework to a 65-year-old patient with chronic SIADH from SCLC (serum Na 119, gradually declining over weeks). Distinguish SIADH (euvolemic, fluid restriction treatment) from cerebral salt wasting (hypovolemic, volume expansion treatment) in a postoperative neurosurgical patient with hyponatremia. Why does the volume status assessment matter clinically?
23. EAH cross-coach integration at Master's depth. Walk the Hew-Butler 2015 Third International EAH Consensus framework as operating clinical decision framework for exercise-associated hyponatremia. Cross-reference Water Master's L3 (hydration clinical research depth), Hot Master's L1 (EHS differential), Move Master's L4 (athletic populations including RED-S intersection), and the Almond 2005 NEJM Boston Marathon foundational study at intervention research methodology depth. Walk the acute management framework — point-of-care sodium at race medical tents, hypertonic saline (3% NaCl 100 mL boluses) for severe symptomatic EAH targeting initial 4-6 mEq/L rise, avoidance of large-volume hypotonic fluid resuscitation which would worsen EAH. Why does the EAH-EHS differential matter?
24. EPA 2024 PFAS and LCRR regulatory frameworks at structural public health depth. Walk the EPA 2024 final National Primary Drinking Water Regulation for PFAS (April 2024) — enforceable MCLs for six PFAS (PFOA 4 ppt, PFOS 4 ppt, PFHxS 10 ppt, PFNA 10 ppt, HFPO-DA 10 ppt, mixtures), compliance by 2029, $9B BIL allocation. Walk the EPA 2024 LCRR (October 2024) — mandatory lead service line replacement within 10 years, action level lowered to 10 µg/L, $15B BIL allocation. Cross-reference Hanna-Attisha 2016 AJPH Flint as foundational environmental injustice case and Marfella 2024 NEJM microplastics in atheroma opening demonstrated-pathology phase. How does the chapter build the water security and environmental health framework at structural public health depth?
25. Bernard 1865 milieu intérieur at clinical translational closure and the multi-tier arc. Walk the Coach Water multi-tier foundational-anchor arc — Bernard 1865 milieu intérieur (Associates field-founding philosophy) → Tigerstedt-Bergman 1898 renin discovery and Snow 1854 cholera map (Associates field-founding methodology) → Agre 1992 Science aquaporin discovery (Bachelor's molecular paradigm) → Heerspink 2020 NEJM DAPA-CKD (Master's clinical intervention) — with Bernard 1865 returning at Master's Lesson 5 operationalized through 21st-century clinical infrastructure (BMP/CMP as routine internal environment assessment, dialysis/Kolff 1944, critical care fluid management via CLASSIC and PETAL CLOVERS, KDIGO frameworks, EPA water policy). Articulate why the multi-tier arc functions as Master's-level curriculum architecture — what does each epistemic axis contribute that the others cannot? How does the four-tier arc accomplish narrative coherence the single-tier curriculum could not?
Continue to Section J — Synthesis Essay.